Question · asked by 1 review
Enamel matrix derivative (EMD; Emdogain) vs placebo or control: PAL gain < 2 mm (dichotomous)
- Population
- Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3 mm
- Intervention
- Enamel matrix derivative (EMD; Emdogain)
- Comparison
- placebo or control
- Outcome
- PAL gain < 2 mm (dichotomous)
Enamel matrix derivative (EMD; Emdogain) led to lower PAL gain < 2 mm (dichotomous) compared with placebo or control (same surgical or non-surgical intervention…; GRADE not reported.
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 2 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Enamel matrix derivative (EMD; Emdogain) vs Placebo or control (same surgical or non-surgical intervention without EMD) PAL gain < 2 mm (dichotomous) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony… · 1 year (time-points 1, 5 and 10 years planned) Enamel matrix derivative (EMD; Emdogain) led to lower PAL gain < 2 mm (dichotomous) compared with placebo or control (same surgical or non-surgical intervention…; GRADE not reported. Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects (2009) · Cochrane All outcomes | RR 0.53 [0.34, 0.82] | 6 studies | GRADE not reported |
Enamel matrix derivative (EMD; Emdogain) vs Placebo or control (same surgical or non-surgical intervention without EMD) PAL gain < 2 mm (dichotomous) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony… · 1 year (time-points 1, 5 and 10 years planned) Enamel matrix derivative (EMD; Emdogain) led to lower PAL gain < 2 mm (dichotomous) compared with placebo or control (same surgical or non-surgical intervention…; GRADE not reported. Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects (2005) · Cochrane All outcomesearlier version CD003875.PUB2, superseded | RR 0.48 [0.29, 0.80] | 5 studies | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes | 2009-02 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.